Processus Wealth & Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.25M Sell
4,818
-1,088
-18% -$646K 1.89% 21
2026
Q2
$2.96M Sell
5,906
-641
-10% -$308K 1.75% 21
2026
Q1
$3.22M Buy
6,547
+12
+0.2% +$6.51K 2.19% 20
2025
Q4
$3.79M Sell
6,535
-16
-0.2% -$9.05K 2.5% 19
2025
Q3
$3.18M Buy
6,551
+264
+4% +$123K 2.28% 20
2025
Q2
$2.55M Buy
6,287
+180
+3% +$75.3K 2.01% 22
2025
Q1
$3.04M Buy
6,107
+134
+2% +$72.6K 2.59% 15
2024
Q4
$3.11M Buy
5,973
+68
+1% +$37.4K 2.48% 16
2024
Q3
$3.65M Sell
5,905
-156
-3% -$92.3K 3.01% 11
2024
Q2
$3.35M Buy
6,061
+107
+2% +$61.3K 2.78% 15
2024
Q1
$3.46M Buy
5,954
+956
+19% +$536K 3.07% 12
2023
Q4
$2.65M Buy
+4,998
New +$2.42M 2.65% 13

Other funds holding TMO

Processus Wealth & Capital Management's TMO Position: Q3 2026 in Review

Processus Wealth & Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 18% in Q3 2026, selling an estimated $646K and leaving 4,818 shares worth $3.25M. The position accounts for 1.89% of the portfolio, ranked #21.

Processus Wealth & Capital Management first reported a position in TMO in Q4 2023 and has held it in 12 quarters since. The position peaked at $3.79M in Q4 2025. 2,797 funds tracked by Wall St. Rank hold TMO as of Q3 2026.

  • Processus Wealth & Capital Management held 4,818 shares of Thermo Fisher Scientific worth $3.25M as of Q3 2026.
  • Processus Wealth & Capital Management sold 1,088 Thermo Fisher Scientific shares in Q3 2026, an estimated $646K.
  • Thermo Fisher Scientific made up 1.89% of Processus Wealth & Capital Management's portfolio in Q3 2026, its #21 holding.
  • Processus Wealth & Capital Management first reported a position in Thermo Fisher Scientific in Q4 2023 and has held it in 12 quarters since.
  • Processus Wealth & Capital Management's Thermo Fisher Scientific position peaked at $3.79M in Q4 2025.
  • 2,797 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2026.

Based on Processus Wealth & Capital Management's 13F filing for Q3 2026, filed 16 Oct 2026.